https://www.statcounter.com/counter/counter.js
Web Analytics
Home » 2017 » December
US FDA approves Spark’s gene therapy Luxturna for rare form of vision loss

US FDA approves Spark’s gene therapy Luxturna for rare form of vision loss

Luxturna FDA approval : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics has secured the approval from the US Food and Drug Administration (FDA) for a rare inherited type of vision loss affecting children and adults that could result in blindness if left untreated. Luxturna is an adeno-associated viral (AAV) vector gene therapy which […]

Mylan’s generic of Allergan's vaginal estrogen cream Estrace gets FDA nod

Mylan has secured the US FDA approval for Estradiol Vaginal Cream USP, 0.01%, the generic version of Allergan’s vaginal estrogen cream – Estrace for the treatment of vulvar and vaginal atrophy. Following the approval of the vaginal estrogen cream, Mylan has announced the launch of Estradiol Vaginal Cream in the US. A condition that normally […]

Continue reading …
Lilly’s ramucirumab fails to crack phase 3 gastric cancer trial

Eli Lilly and Company, which is better known as Lilly, says that a late-stage trial of Cyramza (ramucirumab) for the treatment of a form of gastric cancer met its primary goal of stopping the disease from advancing, but failed in improving overall survival. An antiangiogenic therapy, ramucirumab in combination with cisplatin and capecitabine or 5-FU […]

Continue reading …
Amgen cholesterol drug Repatha bags FDA approval for preventing heart attack and stroke

Repatha FDA approval news : Repatha (evolocumab), the Amgen cholesterol drug has bagged the approval from the US Food and Drug Administration (FDA) for the prevention of heart attacks, strokes and coronary revascularizations in heart disease patients. The Amgen cholesterol injection is a human monoclonal antibody which has been designed to block the activities of […]

Continue reading …